Personalized Medicine Coalition Award for Leadership to be Awarded to Moffitt Cancer Center CEO

October 21, 2010

TAMPA, Fla. – William S. Dalton, Ph.D., M.D., the President, CEO, and Center Director of Moffitt Cancer Center (Moffitt) will receive the 2010 Leadership in Personalized Medicine Award from the Personalized Medicine Coalition (PMC) for his pioneering work putting the concepts of personalized medicine into practice for the benefit of patients.

“Personalized medicine is no longer a promise of the future. It has the capacity, especially in cancer, to ensure that the right patients receive the right treatments at the right time,” noted Edward Abrahams, PMC President. “Under Dr. Dalton’s leadership, Moffitt is paving the way towards a new era of customizing treatments based upon individual characteristics.”  

Dalton is receiving the award in recognition of his leadership in advancing public policies designed to support personalized medicine innovation and clinical application and for Moffitt’s pioneering work to implement personalized medicine concepts both to improve patient outcomes and lower costs.    

“The PMC Board of Directors applauds Dr. Dalton and Moffitt’s leadership in bringing the science of personalized medicine into both clinical practice and public policy” said Wayne A. Rosenkrans, Jr., Chairman of the PMC Board of Directors. “We think that Moffitt demonstrates how all health care facilities will operate in the future.”

A leading advocate for health policies that support personalized medicine for the benefit of patients, Dalton currently serves as the President-Elect of the Association of American Cancer Institutes (AACI) and is Chair of the Science Policy & Legislative Affairs Committee of the American Association for Cancer Research.  In addition, Dalton served on the National Cancer Institute Board of Scientific Advisors as well as multiple scientific advisory boards at cancer centers and research foundations across the United States.

“Dr. Dalton is dedicated to positioning the nation’s cancer centers as major architects of personalized medicine,” said AACI Executive Director Barbara Duffy Stewart. “There is a need to create both guidelines and pathways to effectively implement personalized medicine. Dr. Dalton hopes to achieve this by leveraging the collective influence of AACI’s 95 member cancer centers.”

Dalton’s work is on the leading edge of personalized cancer care and patient-centered outcomes research. Moffitt’s Total Cancer CareTM is an approach to enhancing access to evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care™ is one of the largest cancer tumor bio-repositories and data warehouses in the United States dedicated for use in development of personalized medicine.  

“Moffitt is at the forefront of personalized medicine with its commitment to Total Cancer Care™," said Dalton. "Patients have the opportunity to participate in cutting-edge research to utilize emerging biomarker technology to enhance their care. I am honored to receive this award and look forward to sharing examples of Moffitt’s successes at the Harvard Conference, Personalized Medicine: Impacting Healthcare."

This 6th annual award for personalized medicine will be presented at the Harvard Personalized Medicine Conference, Personalized Medicine: Impacting Healthcare, on Nov. 17 at 11:20 a.m., in Boston, Mass. The conference, which is widely considered the premier event in the field, attracts more than 600 national and international thought leaders. It is a collaboration between Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Harvard Business School.

The PMC Award recognizes an individual whose contributions in science, business, and/or policy have helped advance the frontiers of personalized medicine. Previous recipients of the award include Dr. Janet Woodcock, Director of the Food and Drug Administration’s Center for Drug Evaluation and Research, Dr. Elizabeth G. Nabel, former Director of the National Heart, Lung and Blood Institute at the National Institutes of Health, Michael Leavitt, former Health and Human Services Secretary, Dr. Ralph Synderman, Chancellor Emeritus of Duke University and founder of Proventys, Inc., and, most recently, Brook Byers of Kleiner Perkins Caufield & Byers.

About the Personalized Medicine Coalition

The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. For more information on the Personalized Medicine Coalition, please visit

About Moffitt Cancer Center

Located in Tampa, Florida, Moffitt Cancer Center is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of theNational Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.